Mohanty N K, Malhotra V, Nayak R L, Arora R P
Dept of Urology, Safdarjang Hospital, New Delhi, India.
J Chemother. 2002 Apr;14(2):194-7. doi: 10.1179/joc.2002.14.2.194.
Between July 1994 and July 2001, all patients with superficial transitional cell carcinoma (TCC) of urinary bladder (pT1 and pTa), 7 days after undergoing transurethral resection of tumor were subjected to intravesical instillation of 60 mg BCG (Danish 1331) combined with 5 million IU interferon alpha-2b (Intron-A) mixed with 50 ml of physiological saline weekly for 8 weeks, then fortnightly for 8 weeks, then monthly for 8 weeks, followed by maintenance dose at the end of the 9th, 12th, 18th, 24th months. Each instillation was for 2 h duration with an average follow-up period of 60 months. At the end of the 1st year of follow-up 84% of patients had no tumor recurrence which dropped to 36% at the end of 5-year follow-up, while no incidence of disease progression at the end of the first year was recorded but was 20% at the end of 5 years, thereby resulting in a disease progression-free 5-year interval in 80% of our patients. Drug tolerance was excellent with a very low incidence of toxicity.
1994年7月至2001年7月期间，所有膀胱浅表性移行细胞癌（TCC）（pT1和pTa）患者在经尿道肿瘤切除术后7天，接受膀胱内灌注60mg卡介苗（丹麦1331株）联合500万国际单位α-2b干扰素（干扰能），与50ml生理盐水混合，每周1次，共8周，然后每两周1次，共8周，然后每月1次，共8周，在第9、12、18、24个月结束时给予维持剂量。每次灌注持续2小时，平均随访期为60个月。随访第1年末，84%的患者无肿瘤复发，5年随访结束时降至36%，而第1年末无疾病进展记录，5年末为20%，因此80%的患者实现了5年无疾病进展期。药物耐受性良好，毒性发生率极低。
